外周血单个核细胞
医学
组织因子
纤溶酶原激活剂
法苏迪尔
纤溶酶原激活物抑制剂-1
组织纤溶酶原激活剂
内科学
纤溶
免疫学
内分泌学
药理学
生物
体外
凝结
生物化学
Rho相关蛋白激酶
信号转导
作者
Wenning Li,Wen Chen,Maowei Xie,Haiyang Huang,Huiluan Su,Han Han,Daofa Zhang,Ying Zhang,Xiaohong R. Yang,Wentan Xu,Yan Su,Wei Wu,Yuanxue Huang,Keying Fu,Jiali Wei
出处
期刊:Renal Failure
[Informa]
日期:2016-10-19
卷期号:38 (9): 1359-1363
被引量:4
标识
DOI:10.1080/0886022x.2016.1214053
摘要
Disturbances in hemostasis are common complications of kidney diseases and correlate well with cardiovascular mortality. Little is known about the effects of fasudil on tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) expression in peripheral blood mononuclear cells (PBMCs) in CAPD patients. PBMCs were isolated from 13 individuals with CAPD and 13 healthy subjects. After 4 h of incubation with or without LPS (10 ng/mL), TF and PAI-1 mRNA of PBMCs were detected by RT-PCR. The levels of TF and PAI-1 in culture supernatants of PBMCs were determined by ELISA. Compared with healthy controls, CAPD patients had increased TF, PAI-1 protein and mRNA expression by PBMCs at baseline and after stimulated by LPS (10 ng/mL) [p < 0.001]. The fasudil treatment resulted in a significant effect in decreasing TF and PAI-1 [p < 0.05] synthesis in PBMCs. TF and PAI-1 mRNA expression and activities in PBMCs were increased in CAPD patients. Fasudil reduced LPS-mediated TF and PAI-1 expression and activity in PBMCs. These effects may partially be relevant to the clinical benefits of fasudil in the treatment of CAPD patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI